Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 9Phase 1/2 3Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 5Thoracic 3Gastrointestinal 3Sarcoma 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 120Carboplatin 114Pemetrexed 74Cisplatin 71Nivolumab 68Paclitaxel 58Docetaxel 56Radiotherapy 41Erlotinib Hydrochloride 41Gemcitabine 35Etoposide 34atezolizumab 30osimertinib 29Cetuximab 27Ipilimumab 25Bevacizumab 25Radiosurgery 22durvalumab 21Cyclophosphamide 20Drug Therapy 18130-nm albumin-bound paclitaxel 17avelumab 14Taxes 14Gefitinib 14Albumin-Bound Paclitaxel 14Irinotecan 13Injections 13fludarabine 11Radiation 11cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × AZD 6244 × Thoracic × Clear all
NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02450656 2018-08-27

M14AFS

The Netherlands Cancer Institute

Phase 1/2 Unknown
320 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02025114 2018-07-10

Selumetinib in Combination With Gefitinib in NSCLC Patients

National Taiwan University Hospital

Phase 1/2 Completed
34 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡